Transdermal Patch for Parkinson's Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral combination therapies for Parkinson's disease suffer from unpredictable active substance levels due to varying half-lives, leading to wild fluctuations in effects and increased risk of side effects, as well as compliance issues and undesirable side effects from plasma peak values.
Innovation Solution
Transdermal pharmaceutical preparations combining dopamine agonists, anticholinergics, NMDA receptor antagonists, and monoamine oxidase inhibitors, with optional addition of beta blockers, to maintain consistent plasma levels and reduce side effects through controlled release systems like transdermal therapeutic systems (TTS).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral combination therapy is used to treat Parkinson's disease, then multiple active substances can be administered to improve therapeutic effect, but the varying half-lives of different substances cause wild fluctuations in active substance levels and increase side effects
Solution Approach 1:
The patent combines multiple active substances (L-dopa, decarboxylase inhibitor, and catechol-O-methyl transferase inhibitor) into a single transdermal therapeutic system. This merging approach allows all substances to be delivered simultaneously through the skin at controlled rates, eliminating the plasma peak fluctuations that occur with oral administration of separate substances.
Solution Approach 2:
The transdermal system acts as an intermediary delivery mechanism between the active substances and the bloodstream. Instead of oral absorption with its inherent kinetic variability, the transdermal patch provides a controlled, steady release of substances directly into the systemic circulation, smoothing out concentration fluctuations.
2Reliability
If oral combination therapy is used, then comprehensive Parkinson's disease treatment is achieved, but patient compliance becomes difficult due to complex dosage intervals and haphazard intrinsic kinetics
Solution Approach 1:
Multiple active substances with different pharmacokinetic profiles are merged into a single transdermal patch that can be worn for extended periods (e.g., 24 hours). This eliminates the need for patients to remember and administer multiple separate medications at different intervals, dramatically improving compliance while maintaining the synergistic therapeutic effects of the combination.
3Power
If L-dopa is administered orally to treat Parkinson's disease, then potent dopaminergic effect is achieved, but dyskinesias and loss of action occur after long-term use
Solution Approach 1:
The patent replaces the oral administration mechanism with transdermal delivery. This substitution changes the absorption kinetics from the gastrointestinal tract to transdermal diffusion, providing more stable plasma levels of L-dopa over time. The steady-state delivery prevents the peak-trough fluctuations that lead to dyskinesias and tolerance development, enabling sustained long-term therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal approach ensures consistent active substance levels, reduces side effects, and simplifies compliance by providing a safer and more reliable combination therapy for Parkinson's disease, allowing for adjustable treatment based on disease stage and symptom severity.
Implementation Method 1
transdermally administrable pharmaceutical preparations
Data Source
AI summary
The transdermal pharmaceutical preparations for the treatment of Parkinson's disease contain a combination of at least two active substances selected from the following groups of active substances: dopamine agonists and L-dopa, monoamine oxidase inhibitors, anticholinergics, NMDA-receptor antagonists, sympathomimetics; at least two of the said active substances being members of different active substance groups.